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Psoriasis vulgaris (PV) is a cutaneous inflammatory disorder stemming from abnormal, persistent activation of the interleukin-
(IL-)23/Th17 axis. Pustular psoriasis (PP) is a clinicopathological variant of psoriasis, histopathologically defined by the
predominance of intraepidermal collections of neutrophils. Although PP pathogenesis is thought to largely follow that of (PV),
recent evidences point to a more central role for IL-1, IL-36, and IL-6 in the development of PP. We review the role of IL-6 in the
pathogenesis of PV and PP, focusing on its cross-talk with cytokines of the IL-23/Th17 axis. Clinical inhibitors of IL-6 signaling,
including tocilizumab, have shown significant effectiveness in the treatment of several inflammatory rheumatic diseases, including
rheumatoid arthritis and juvenile idiopathic arthritis; accordingly, anti-IL-6 agents may potentially represent future promising
therapies for the treatment of PP.
1. Introduction
Psoriasis is an immune-mediated cutaneous disease with
an estimated prevalence of approximately 2% in the Euro-
pean and North American population [1, 2]. The most
common clinical presentation of psoriasis, namely, psoriasis
vulgaris (PV), is defined by multiple erythematosquamous
plaques, histologically characterized by (1) epidermal acan-
thosis, hyperkeratosis, and parakeratosis; (2) dilated capillary
network in the papillary dermis; (3) a mixed inflamma-
tory infiltrate including polymorphonuclear cells, as well
as intraepidermal collections of neutrophils [3]. Epidermal
clusters of neutrophils have been given eponymous names
such as Munro’s microabscesses and Kogoj pustules [3].
Various evidences deriving from genetic studies, adoptive
transfer models, and molecular evaluation of human samples
point to a key pathogenetic role for T helper-1 (Th1)/Th17 cells
and related cytokines (including TNF-alpha, IL-17, and IL-
22), as well as formyeloid cell-derived cytokines such as IL-12
and IL-23 [1, 2, 4–8].
Pustular psoriasis (PP) is a clinicopathological variant
of psoriasis distinguished by the following features: (1)
clinically, presence of pustules on variably erythematous
skin; (2) histopathologically, predominance of intraepidermal
collections of neutrophils [9–11]. Any bioptic sample pre-
senting the histologic picture of PP should always undergo
further investigations to rule out the eventuality of superfi-
cial dermatophytosis or Candida albicans infection, whose
histopathologic features are often indistinguishable from
those of PP [12, 13].
PP has been classified into generalized and localized
forms [14]. Generalized PP is a life-threatening, systemic
inflammatory condition characterized by repeated attacks of
diffuse, erythematous, pustular rash associated with high-
grade fever, general malaise, and frequent extracutaneous
organ involvement; possible laboratory testing abnormalities
include leukocytosis with left shift, increased erythrocyte
sedimentation rate (ESR), or increased C-reactive protein
(CRP) [14, 15]. Acute flare-ups of generalized PP may be
triggered by pregnancy status, infection, or exposure to drugs
[15].Though generalized PP formally belongs to the psoriasis
spectrum because of its frequent clinical association with
PV and multiple similarities in molecular pathogenesis, it
is debated whether it may represent a distinct clinicopatho-
logical entity [16, 17]. Another controversy is related to the
classification of generalized PP alone or accompanied by PV
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as distinct subtypes with different etiologies [17]. Likewise,
localized PP, which is often limited to palms and soles
(i.e., palmoplantar pustulosis), has been regarded by several
authors as a separate entity rather than a clinical variant
of psoriasis [17, 18]. However, a close relationship between
localized PP and PV is likely suggested by lack of significant
epidemiologic differences, frequent coexistence in the same
patients, and largely shared genetic background [18].
Conventional first-line therapies for PP include topical
corticosteroids, phototherapy, acitretin, cyclosporine, and
methotrexate [14, 16]. Because the use of therapeutics is often
hampered by low efficacy and/or adverse effect profile, a need
to develop novel therapeutic approaches for PP is arising [14].
Infliximab is actually recognized by many experts as a first-
line treatment option for PP, especially in severe cases [14, 19,
20]. Nonetheless, paradoxical TNF-alpha inhibitor–induced
PP is a newly occurrence, whose pathogenic mechanism is
still relatively unclear [21, 22].
The pathogenic process underlining PP development is
only partially shared with PV [16, 17]. The efficacy of TNF-
alpha inhibitors in most patients with PP or PV points
to a crucial role of TNF-alpha in their pathogenesis [14].
In addition to TNF-alpha, alternative signaling pathways
relevant to PP include those mediated by IL-17 and the
IL-1/IL-36 family [17, 23–25]. Furthermore, recent evidence
seems to indicate IL-6 as a new druggable target for PP [23].
2. Psoriasis Pathogenesis: Current Concepts
2.1. The IL-23/Th17 Axis in the Pathogenesis of Psoriasis. A
distinct lineage of IL-23-responsive CD4+ T cells secreting
IL-17A and IL-17F and expressing the lineage-specific tran-
scription factor RORC has been recently identified as Th17
cells [1, 5, 26–28]. Additional effector cytokines produced
by Th17 cells include IL-21 and IL-22, as well as other
non-Th17-specific cytokines, such as IL-6 [29–31]. Cytokine
requirements for inducing Th17 differentiation are similar in
mice and humans [26, 32]. Naive CD4+ T-cell activation in
the presence of both TGF-beta and IL-6 is key to priming
the initial differentiation into Th17 cells [2, 27]. TGF-beta
also exerts an indirect action through suppression of T-bet-
dependentTh1 differentiation [2, 26]. IL-6-dependent STAT3
activation plays an essential role in Th17 differentiation by
initially inducing the transcription of RORC, IL17, and IL23R
genes and later promoting the expansion of differentiated and
memory Th17 cells [26, 32]. However, TGF-beta and IL-6-
drivenTh17 cells are weakly functional without further expo-
sure to IL-23; the latter cytokine is crucial for differentiation
into effector cells, lineage stabilization, and full maturation to
inflammatoryTh17 cells [2, 5, 27, 28, 33].
Psoriasis skin lesions are the result of complex inter-
actions between dendritic cells (DCs), keratinocytes, and
Th1/Th17 lymphocytes [30, 34, 35]. Recent pathogenicmodels
of psoriasis emphasized the role of IL-23/Th17 axis [1, 2, 5, 36].
IL-23 production by inflammatory DCs and activated ker-
atinocytes stimulates Th17 cells within the dermis to release
proinflammatory mediators such as IL-17 and IL-22 that, in
turn, activate resident tissue cells, particularly keratinocytes
[33, 35]. Psoriatic plaques harbor higher levels of IL-23p19 and
IL-12/23p40 than those of IL-12p35 [1, 27]; polymorphisms
in IL12/23p40 and IL23R genes are associated with increased
risk of developing psoriasis, and injection of recombinant IL-
23 into healthy skin results in inflammatory changes with
histologic features of psoriasis [5, 30]. According to this
evidence, the pathogenic relevance of IL-23 has been also
confirmed by the high efficacy of both anti-IL-12/IL-23p40
monoclonal antibodies (i.e., ustekinumab) and IL-23p19 neu-
tralizing agents (i.e., tildrakizumab) [8, 27, 33, 37, 38].
IL-17A (simply known as IL-17) belongs to the IL-17
cytokine family, which includes six members (from IL-17A
to IL-17F) [1, 2]. IL-17A shows similar pleiotropic effects
acting on a wide range of nonimmune cells, resulting
in the induction of different proinflammatory cytokines,
chemokines, antimicrobial peptides, nitric oxide, and matrix
metalloproteinases [1, 2, 30, 34]. IL-17 is able to induce IL-
6, IL-8, and CXCL5 in human skin keratinocytes, indirectly
promoting the differentiation, activation, and migration of
neutrophils [5, 34, 35]. Bioptic samples fromPVplaques show
elevated levels of IL-17 in parallel with increased expression
of IL-23 and IL-22, while serum levels of IL-17 are correlated
to psoriasis severity [2, 6, 30, 39]. IL-22 is another key down-
stream cytokine in the IL-23/Th17 axis, being upregulated in
psoriatic skin as compared to normal skin [5, 29, 40, 41]; IL-
22 mediates keratinocyte hyperplasia via STAT3 activation,
leading to psoriasiform hyperplasia. In the absence of IL-
22, severity of both IL-23-mediated and imiquimod-induced
psoriasis-like dermatitis in corresponding mouse models is
markedly reduced [40, 42, 43].
A significant increase in IL-17 expression has been
detected in lesional skin of PP, despite the absence of any
significant increase in IL-12/IL-23 levels [44]; this is strikingly
different from PV, where increased IL-17 levels are typically
mirrored by analogous changes in IL-12/IL-23 expression [7,
37, 43]. Accordingly, conventional Th17 may not be the main
driver for increased IL-17 expression in PP, with neutrophils
being a possible, alternative source of IL-17 [23, 44]. Indeed,
the anti-IL-23 agent ustekinumab appears to be significantly
less effective in the treatment of PP than that of PV [44–
46]. Of note, the immunopathology of two well-known
histologic mimics of PP, that is, superficial dermatophytosis
andmucocutaneousCandida albicans infection, relies heavily
on the production of IL-17, as suggested bymousemodels and
rare human patients with loss-of-function defects in the IL17
gene [47–50]. It is now clear that IL-17-dependent recruit-
ment of neutrophils and secretion of antimicrobial peptides
are crucial for cutaneous protection against dermatophytic
infections and Candida albicans [47, 49–51]. Importantly, the
cellular sources of IL-17 production in this setting are not
limited to conventional CD4+T cells, as several components
of the innate immunity (gamma/delta T cells, mast cells,
and neutrophils) appear to be capable of immediate IL-17
secretion prior to the contribution of IL-23-dependent Th17
adaptive immunity [42, 48–52].
2.2. IL-36 and Pustular Psoriasis. Pathogenic IL36RN gene
mutations have been identified in familiar and sporadic cases
of PP, either generalized or localized [25, 53, 54]; IL36RN
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encodes the IL-36 receptor antagonist (IL-36Ra), a soluble
mediator that antagonizes the proinflammatory activity of
IL-36 cytokines (IL-36-alpha, IL-36-beta, and IL-36-gamma)
through binding IL-36R (IL-1RL2) and inhibiting IL-36-
dependent activation of NF-kappaB signaling [25, 55–57].
Several authors have detected elevation of keratinocyte-
derived IL-36 cytokines levels in psoriatic lesional skin,
as a result of keratinocyte stimulation by IL-17, IL-22,
and TNF-alpha [58–60]. Primary epidermal IL-36 over-
expression in transgenic mouse models results in PV-like
phenotype histopathologically characterized by acanthosis,
hyperkeratosis, and mixed inflammatory infiltration with
predominance of neutrophils [55, 59]; further crossing with
IL36RN-knockout strain augments IL-36 signaling leading
to increased neutrophil infiltration and a histopathological
picture more akin to classic PP [25, 55, 61]. Furthermore, loss
of IL-36R signaling successfully counteracts development of
imiquimod-induced psoriasiform dermatitis, pointing to a
crucial role of IL-36 ligands in the proinflammatory activity
of the IL-23/Th17 axis [61, 62]. Indeed, IL-36R signaling is
relevant for the expansion of IL-17-producing T helper cells
[25, 55].
IL-36 cytokines may exert a direct effect on immune cells
[55]; activation of IL-36R, which is expressed constitutively
on DCs, CD4+ T cells, and macrophages, promotes matu-
ration of monocyte-derived DCs and induction of several
cytokines, including IL-1, IL-6, IL-23, TNF-alpha, and IFN-
gamma [59, 61, 63]. In addition, keratinocytes in psoriasis
as well as synoviocytes in RA are capable of responding to
direct IL-36 ligands stimulationwith production of IL-6, IL-8,
and antimicrobial peptides, which cooperate with IL-17A and
TNF-alpha promoting neutrophil activation and migration
[11, 54, 56, 60].
Thus, IL-36 ligands not only act as effector cytokines of
the IL23/Th17 axis, but also induce several proinflammatory
mediators (including IL-6, IL-8, and IL-23) that reinforce
the Th17-driven inflammatory milieu [25, 59, 60, 63]. The
cross-talk between IL-36 ligands and Th17 mediators estab-
lishes a positive feedback loop involving keratinocytes, DCs,
macrophages, andTh17 [60, 61]; as a consequence, activation
of T cells is enhanced, recruitment of immune cells in
psoriatic lesions is augmented, and the IL-23/Th17 axis is
reinforced [55, 60]. In keeping, elevation of IL-36R ligands
in psoriatic plaques is closely correlated with increased levels
of TNF-alpha, IL-17, and IL-22, confirming the existence
of a proinflammatory, self-reinforcing gene expression loop
[56, 59].
Pathogenetic IL36RN mutations associated with PP abol-
ish the antagonistic effect of IL-36Ra, enhancing the IL-36-
dependent production of IL-1, IL-6, and IL-8 [25, 54]. Indeed,
patients with IL36RN-dependent genetic predisposition to
PP have been treated effectively with anakinra, an IL-1
antagonist [64]. Nonetheless, so far no specific data regarding
effectiveness of IL-6 inhibitors in IL36RN-dependent PP are
available. Overall, recessive IL36RN mutations are associated
with increased risk of PP alone, but not PV [57, 65–67]; both
phenotypic variance and incomplete penetrance have been
observed, supporting the notion that IL36RN mutations are
able to inducemanifest disease only in the presence of specific
environmental factors and/or further genetic defects at a
second disease locus [25, 53, 65]. All genetic follow-up studies
of PP patients have found evidence of genetic heterogeneity,
proving that IL36RN mutations account for only a minority
of sporadic PP cases [25, 57, 66].
3. IL-6 Signaling and Pustular Psoriasis
3.1. IL-6 Signaling and Selective IL-6 Inhibition. IL-6, a
pleiotropic, proinflammatory cytokine, is the archetypal
member of the gp130-related cytokine family, which also
includes IL-11, IL-27, OSM, CNTF, CT-1, LIF, and CLC [68,
69]. IL-6 exerts its activity through interactionwith a receptor
complex composed of the nonsignaling alpha subunit IL-
6R (CD126) and the common, ubiquitously expressed, beta
subunit gp130 (CD130), resulting in immediate activation
of receptor-associated kinases (JAK1/JAK2 and TYK2) and
subsequent regulation of STAT1/STAT3 and SHP2-MAPK
signaling pathways (Figure 1) [68, 70, 71]. The IL-6R subunit
functions in vivo as both a conventional membrane-bound
receptor, expressed on the surface of hepatocytes and certain
inflammatory cells, and a soluble form (sIL-6R) which forms
active IL-6/sIL-6R complexes (IL-6 transsignaling) [72, 73];
this property is unique to IL-6 among currently known
cytokines [68–70].
In addition to being a major stimulus for the synthesis
of acute-phase proteins, IL-6 promotes differentiation of B
cells into mature plasma cells as well as T-cell differentiation
and activation [69, 72]. Importantly, recent evidence demon-
strated that IL-6 exerts a positive influence in initiating Th17
cell development, whereas it inhibits TGF-beta-dependent
differentiation of regulatory T cells [32, 74]. IL-6 is also a
downstream target gene of IL-17 signaling in nonimmune
cells such as keratinocytes and fibroblasts [35, 72, 75]; this
positive IL-6/IL-17 loop plays a key role in proinflammatory
interactions between the immune system and nonimmune
tissues [32, 76]. Additionally, IL-6 exerts a significant influ-
ence on myeloid precursor cells and circulating neutrophils
[69, 77–79]: IL-6 promotes differentiation from myeloid
progenitors to neutrophils as well as neutrophilia [80].
Furthermore, IL-6 secretion results in secondary production
of chemokines such as IL-8 and MCP-1 by mononuclear
cells/macrophages as well as expression of ICAM-1 and
other adhesion molecules on endothelial cells, leading to
enhanced neutrophil migration [75, 77, 79]. Last, mature
neutrophils respond to IL-6 via membrane-bound IL-6R,
releasing proinflammatory cytokines such as IL-23 and IL-
17 and establishing a Th17-polarizing positive feedback loop
[32, 76].
Transgenic IL6-KO mouse models are characterized by
a unique resistance to several inflammatory conditions such
as experimental autoimmune arthritis or encephalomyelitis
[69, 70]; accordingly, IL-6 plays a central role in the pathogen-
esis of several autoimmune diseases, including rheumatoid
arthritis, juvenile idiopathic arthritis, adult onset Still’s dis-
ease, systemic lupus erythematosus, Takayasu’s arteritis, and
inflammatory bowel disease [69, 72, 75]. As a consequence,
IL-6 has gained attention as an attractive therapeutic target
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Figure 1: IL-6 signalling pathways. In classical signalling (red star), cells expressing membranous IL-6R are responsive to IL-6; in
transsignalling (yellow star), cells lacking IL-6R are activated by IL-6/sIL-6R complexes (sIL-6R is generated by proteolytic shedding from
IL-6R via ADAM10 and ADAM17 or by mRNA alternative splicing). Cellular events initiated by IL-6/IL-6R activity include activation of
JAK, MEKs-ERKs, and PI3K/Akt kinases, resulting in changes in nuclear gene expression. IL-6: interleukin 6; sIL-6R: soluble interleukin 6
receptor.
for autoimmunity, leading to the clinical development of
anti-IL-6R agents such as tocilizumab [72, 81]. Tocilizumab
is a monoclonal antibody which globally blocks IL-6 bio-
logic activity by antagonizing both conventional membrane-
bound signaling and sIL-6/IL-6R transsignaling, resulting in
a strong inhibition of IL-6-dependent STAT1/STAT3 activa-
tion [70]. Tocilizumab is an established therapeutic option
for rheumatoid arthritis and juvenile idiopathic arthritis,
although the field of tocilizumab-responsive autoimmune
conditions is still expanding [68, 69, 81, 82].
3.2. IL-6 in the Pathogenesis of Psoriasis. IL-6 has long been
associated with psoriasis pathogenesis [83–85]. In addi-
tion to known psoriasis susceptibility loci encoding pro-
teins engaged in the TNF-alpha, IL-23, and IL-17 signaling
pathways (including HLA-Cw6, IL23R, IL12B, IL23A, and
TNFAIP3 genes), IL6 and STAT3 polymorphisms have been
linked with hereditary predisposition of developing psoriasis
and response to TNF-alpha inhibitors [33, 86–89]. Increased
skin and serum IL-6 levels are a feature of psoriasis [39,
84, 90]. Serum levels of IL-6 are regarded as a marker of
the inflammatory activity in psoriasis as well as an indicator
of treatment response [4, 39, 84, 85]; a positive correlation
between IL-6 serum levels and clinical severity of PV before
treatment has been described [4, 90]. Additionally, serum
IL-6 levels have been reported to decrease after effective
treatment with methotrexate or UVB phototherapy [91, 92].
Furthermore, the likelihood of a positive Ko¨ebner reaction
has been reported to correlate with higher proportions of IL-
6+ mast cells and IL-6R+ cells in the dermis [93].
IL-6 is produced by a wide range of cell types in psori-
atic plaques (including keratinocytes, fibroblasts, endothelial
cells, DCs, and macrophages) in response to several stimuli,
such as IL-1, TNF-alpha, IL-17, and IL-36 (Figure 2) [84,
94–96]. Human keratinocytes stimulated by IL-17 or IL-
36 may serve as a significant source of IL-6 [35, 76, 85,
94]; furthermore, a population of dermal slan-DCs has
been recently identified as proinflammatory myeloid DCs
in psoriatic skin lesions, which is capable of producing
significant levels of IL-6 together with TNF-alpha, IL-1b,
IL-23p19, and IL-12p70, all of which have proven crucial
for the polarization of pathogenic Th17 and Th1 cells [95].
Importantly, the synergistic effects of IL-17 and TNF-alpha
are capable of further upregulating IL-6 in psoriasis lesional
skin; hence, selective targeting of either IL-17 or TNF-alpha
exerts additional beneficial effects by indirectly reducing IL-
6 levels [32, 35, 94, 96].
The key pathogenetic role of IL-6 signaling pathway in
psoriasis is supported by evidence deriving from mouse
models of psoriasis-like skin disease relying on constitutive
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activation of STAT3 in keratinocytes [71, 97, 98]. Increased
activation of STAT3 (pSTAT3) has been detected in lesional
skin of psoriatic patients [98]; several cytokines upregu-
lated in psoriasis, including IL-6, IL-20, and IL-22, signal
through STAT3 activation [71, 98]. STAT3 phosphorylation
influences the expression of genes controlling keratinocyte
survival and proliferation through interactions with other
transcription factors such as NF-kappaB [96, 99]. STAT3
activation has a key role in the psoriasis-associated IL-23
signaling cascade [71, 97, 99]. Accordingly, JAK inhibition is
being assessed as a novel therapeutic strategy for treatment of
psoriasis. Importantly, IL-6 produced by DCs, macrophages,
T cells, and keratinocytes further augments the IL-6-rich
microenvironment in psoriatic plaque, resulting in the robust
induction of pSTAT3 in effector and memoryTh17 cells [76].
Persistent pSTAT3 signaling in T cells is required for initial
Th17 differentiation and promotion of Th17 cytokines pro-
duction, unleashes unrestrained activation of effector T cells,
and prevents suppressive activity of T regulatory cells [76].
Additionally, IL-6-mediated pSTAT3 signaling is capable of
enhancing keratinocyte growth and proliferation, promoting
psoriasis epidermal hyperplasia [96, 98]; IL-6 signaling on
keratinocytes also induces chemoattractant proteins via AP-1
downstream activation [97].
IL-6 is a key mediator of IL-23/Th17-driven cutaneous
inflammation [37, 94]. IL-23-induced dermal inflammation
in psoriasis mouse models relies on T cells and IL-6 [96]. In
IL-6-deficient mice, intradermal injections of IL-23 lead to
increased IL-22 production comparedwithWTmice, but this
response is not sufficient for effective dermal inflammation
and epidermal hyperplasia [96]. This finding seems to be
secondary to insufficient expression of IL-22R1A in the
absence of IL-6. The increased level of IL-6 in the skin of
imiquimod-treated lL17RA-del mice compared with treated
WT skin confirms the role of IL-6 in disease development in
the absence of IL-17 signaling [41]. Accordingly, imiquimod is
thought to indirectly activate the preexisting IL-17-producing
T cells, which are capable of secreting other cytokines such
as IL-6 that drive development of psoriasiform dermatitis
independent of IL-17 [41, 43].
3.3. IL-6 and Pustular Psoriasis. Recent evidence points to
an unexpected, central role of IL-6 in driving the abnormal
recruitment of neutrophils into lesional skin of PP [23];
accordingly, IL-6 would be the key downstream mediator
acting together with IL-17 to induce excessive skin infiltration
by neutrophils resulting in intraepidermal pustules typical
of PP (Figure 2) [23]. Importantly, IL-6 could be a novel,
attractive target for the treatment of PP, in the light of the
current availability of biologic agents safely and effectively
antagonizing IL-6.
IL-6 has been long known to favor neutrophil differentia-
tion and activation both in vivo and in vitro [79, 80]. Positive
correlations have been recorded between IL-6 serum levels
and clinical severity of PP, as well as associated leukocytosis,
ESR, and CRP levels [100, 101]. Clinical improvement of
PP following tonsillectomy has been paralleled by reduction
of serum IL-6 levels [102]; in keeping, in vitro exposure of
tonsillar mononuclear cells to streptococcal antigens resulted
in increased production of IL-6 [91, 103].
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The K14-IL17A-ind/+ transgenic mouse represents an
animal model of psoriasiform dermatitis characterized by
deregulated, persistent overexpression of IL-17A in epider-
mal keratinocytes leading to prominent development of
intraepidermal neutrophil microabscesses in addition to
dermal T-cell infiltration, hyperkeratosis, and parakeratosis
[23]. The immunopathogenesis observed in the K14-IL17A-
ind/+ strain strongly supports a mechanism whereby IL-
6 propagates IL-17-induced inflammation, as confirmed by
the noticeable presence of IL-6R𝛼-expressing monocytes and
neutrophils in the affected skin [23].
In this setting, the inflammatory cascade starts with
epidermal IL-17A expression in the absence of IL-23 overex-
pression; similar conditions (i.e., a high IL-17A/IL-23 ratio)
have been described as characteristic of bioptic samples
of human PP compared to conventional PV (whereby IL-
17A levels appear to follow those of IL-23). The persistent
expression of IL-17A in basal keratinocytes seems to induce
target cell to secrete significant amounts of IL-6, resulting in
high levels of circulating IL-6 and sIL-6/IL-6R heterodimers
[23]; increased levels of local and systemic IL-6 influence
IL-6R-alpha+ neutrophils and monocytes activity, leading
to aberrant chemotaxis into lesional skin and formation of
intraepidermal neutrophil microabscesses [23].
Importantly, administration of anti-IL-6 neutralizing
antibody in K14-IL17A-ind/+ mice is sufficient to reduce
and prevent the extent of leukocyte infiltration, leading to
a sizeable decrease in cutaneous accumulation of myeloper-
oxidase+ CD11b+ cells, intraepidermal neutrophil microab-
scesses formation, and epidermal changes [23]. Hence, IL-6
seems to play a key role in the innate component of IL-17-
driven PP-like dermatitis, and blockade of IL-6 activity may
result in dramatic clinicopathological improvements despite
the persistent activation of the IL-17 signaling.
Interestingly, gene expression evaluation of psoriatic
plaques in the initial 48 hours after anti-TNF-alpha inflix-
imab administration revealed significant inhibition of slan-
DC-derived IL-1b, TNF-alpha, IFN-gamma, IL-12, and IL-
23 but not IL-6, suggesting that direct TNF-alpha blockade
is less effective in targeting IL-6 production by inflamma-
tory dermal DCs [95]. If IL-6 signaling was more relevant
to PP development than to PV, such data would provide
an explanation to clinical evidence that efficacy rates of
TNF-alpha inhibitors in PP are lower as compared to PV
[14].
4. Conclusions
So far, the experience with IL-6 inhibitors in psoriasis is
limited, as other signaling pathways have been successfully
investigated as therapeutic targets (i.e., TNF-alpha, IL-23,
and IL-17) [8, 36, 38, 104]. Furthermore, paradoxical cases of
biologic-induced psoriasiform dermatitis have been reported
also for patients undergoing treatment with tocilizumab for
RA [105, 106]. Tofacitinib and other Janus kinase inhibitors
(targeting, among the others, also the IL-6R signaling path-
way) are gaining significant attention as therapeutic options
in psoriasis, but their efficacy in PP is still unclear [107, 108].
Only occasional patients with generalized PP, including para-
doxical anti-TNF-induced cases, have been effectively treated
with the anti-IL-6 agent tocilizumab [109, 110]. A larger
amount of data exists with regard to the role of IL-1 antagonist
anakinra in PP, especially in cases secondary to IL36RN
mutations [24, 62, 64]. Nonetheless, it seems reasonable that
IL-6may play a crucial role as well as IL-1 independently from
the persistent IL-36R activation in the epidermis [62]. If this
evidence will be confirmed, agents neutralizing IL-1 and IL-6
may be effective in treating PP, similarly to juvenile idiopathic
arthritis, which has been successfully treated with either anti-
IL-1 agents or IL-6 inhibitors [82].
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